NRC Health (NRC)
NRC trades on Nasdaq in Health Care, Biotechnology: Commercial Physical & Biological Resarch. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/70487/000143774926007002/0001437749-26-007002-index.htm. Net income: SEC 10-K (us-gaap:ProfitLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | NRC on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Commercial Physical & Biological Resarch |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0000070487 |
| SEC industry code | Services-Commercial Physical & Biological Research |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $137.4M |
| Net income | $11.6M |
| Operating income | $22.6M |
| Net margin | 8.4% |
| Operating margin | 16.4% |
| Revenue growth | -4.0% |
| Cash | $4.1M |
| Total assets | $134.9M |
| P/E (computed) | 48.2× |
| P/S (computed) | 4.1× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-04 |
| Cash and burn | $3.6M cash; operating cash flow $5.9M a quarter. | Report 2026-09-30 |
| Shares outstanding | 21,221,538 (2026-10-31); 22,657,421 a year earlier; 24,558,330 three years earlier. | Cover page 2026-10-31 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | KPMG LLP, Omaha, Nebraska, United States | PCAOB Form AP 2026-04-07 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $98K, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $38.4M | $4.7M | $8.0M | $3.6M | $102.9M | $143.8M | 10-Q 2026-11-04 |
| Q2 2026 2026-06-30 | $35.4M | -$3.3M | $1.4M | $3.3M | $90.0M | $140.0M | 10-Q 2026-08-04 |
| Q1 2026 2026-03-31 | $34.8M | $3.2M | $7.2M | $2.5M | $74.0M | $138.6M | 10-Q 2026-05-06 |
| Q4 2025 2025-12-31 | $35.2M | $1.8M | $7.2M | $4.1M | $79.0M | $137.4M | 10-K 2026-03-05 |
| Q3 2025 2025-09-30 | $34.6M | $4.1M | $13.8M | $2.2M | $76.0M | $139.1M | 10-Q 2026-11-04 |
| Q2 2025 2025-06-30 | $34.0M | -$106K | -$1.1M | $5.3M | $77.0M | $140.3M | 10-Q 2026-08-04 |
| Q1 2025 2025-03-31 | $33.6M | $5.8M | $6.6M | $2.5M | $58.7M | $141.3M | 10-Q 2026-05-06 |
| Q4 2024 2024-12-31 | $36.9M | $6.6M | $6.4M | $4.2M | $57.9M | $143.1M | 10-K 2026-03-05 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document FORM 424B7 | 424B7 | 2026-05-13 |
| Latest annual report FORM 10-K/A | 10-K/A | 2026-04-28 |
| Latest quarterly / interim FORM 10-Q | 10-Q | 2026-11-04 |
| Latest current report FORM 8-K | 8-K | 2026-10-27 |
| Latest proxy FORM DEFA14A | DEFA14A | 2026-05-08 |
Source: SEC EDGAR submissions feed, 1,000 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +2.7% |
| 1 month | +31.7% |
| 3 months | +24.6% |
| Year to date | +41.5% |
| 1 year | +70.9% |
| From 52-week high | -1.9% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Commercial Physical & Biological Resarch
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| OABI | OmniAb Inc. | $4.89 | -0.41% | $713.3M |
| ABSI | Absci Corporation | $7.47 | -11.54% | $1.3B |
| MXCT | MaxCyte Inc. | $1.18 | -0.84% | $121.8M |
| ONMD | OneMedNet Corp | $4.86 | -8.99% | $29.2M |
| ICLR | ICON plc | $191.40 | -1.67% | $14.7B |
| CRL | Charles River Laboratories International Inc. | $335.52 | -0.72% | $16.1B |
| MEDP | Medpace Holdings Inc. | $648.20 | -0.88% | $18.1B |
| INCY | Incyte Corp. | $120.27 | -0.58% | $24.5B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier